金斯瑞生物科技今日盘中大涨6.32%，引起了市场的广泛关注。
消息面上，公司发布了截至2025年12月31日止的年度业绩报告，期内取得收益9.6亿美元，同比大幅增加61.4%，主要归因于许可收益的大幅增长以及其他业务的稳健表现。收益的强劲增长带动公司毛利显著上升，持续经营业务的毛利约为5.53亿美元，较上期增长103.3%。
此外，公司的联营公司传奇生物表现亮眼，其核心产品CARVYKTI在2025年销售额达到18.87亿美元，同比增长96%。同时，传奇生物的亏损大幅收窄至0.33亿美元，并有望在2026年实现盈利。这一系列积极因素共同驱动了市场对公司整体盈利前景的乐观预期，从而推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.